Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Search Results - therapeutics

4 Results Sort By:
High potency recombinant IGF-1 biologic
Optimized IGF-1 isoforms have been developed with improved potency in producing muscle hypertrophy. Problem: Insulin-like growth factor I (IGF-I) is a key regulator of muscle development and growth. However, the complexity of IGF-1 activity is modulated by extensive alternative splicing and glycosylation. Solution: A former Penn researcher,...
Published: 3/20/2020   |   Inventor(s): Elisabeth Barton
Keywords(s): Therapeutics
Category(s): Therapeutics & Vaccines
Antibody-like therapeutic platform with effector function
Technology Overview: While antibody therapeutics have proven to be successful in recent years, they are not without drawbacks. The large size of antibodies can prevent their effective use against certain cancers, as well as prevent them from crossing the blood-brain barrier. Additionally, many antibodies require post-translational modifications and...
Published: 3/18/2020   |   Inventor(s): Mark Greene
Keywords(s): Antibody, Therapeutics
Category(s): Therapeutics & Vaccines
Novel compounds for treatment for Friedreich Ataxia
New compounds identified through high throughput screening which improve mitochondrial function of Friedreich ataxia cells. Technology Overview: Friedreich ataxia (FA) is an autosomal recessive, inherited neuro- and cardio-degenerative disorder characterized by progressive ataxia of all four limbs, skeletal deformities, and hypertrophic cardiomyopathy....
Published: 3/16/2020   |   Inventor(s): Robert Wilson
Keywords(s): Neurodegenerative Diseases, Orphan Disease, Pharmaceuticals, Therapeutics
Category(s): Therapeutics & Vaccines
Immunotoxin Therapeutic Targets Epithelial Derived Cancers
Immunotoxin chimeras of DNaseI and cytolethal distending toxin (CdtB subunit) are an effective therapeutic against epithelial tumors. Technology Overview: Immortalized epithelioid cell lines are sensitive to CdtB, whereas cells of mesenchymal, or ectomesenchymal origin are relatively resistant. Unique chimeras of the cdtB gene and human type I...
Published: 11/27/2018   |   Inventor(s): Joseph Dirienzo
Keywords(s): Immunotherapy, Oncology, Therapeutics
Category(s): Therapeutics & Vaccines